New pill CT7439 enters human testing for Hard-to-Treat cancers
NCT ID NCT06600789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. It is too early to know if CT7439 will shrink tumors or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT7439 (an experimental cancer drug taken as a capsule by mouth)
What this could lead to
If it works, this could point toward a new treatment option for people with solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, small trial (50 people) focused mainly on safety and dosing. It is too soon to know if CT7439 will be effective or have manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research site 01
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research site 02
RECRUITINGFairfax, Virginia, 22031, United States
-
Research site 03
RECRUITINGDallas, Texas, 75230-2571, United States
-
Research site 04
RECRUITINGOxford, OX37LE, United Kingdom
-
Research site 05
RECRUITINGManchester, M20 4GJ, United Kingdom
-
Research site 06
RECRUITINGSutton, SM2 5PT, United Kingdom